Collaborative Innovation in Pharmaceutical Industry: Approaches and Requirements

Abstract

The pharmaceutical industry needs to consider new approaches to tackle the R&D output challenge it is currently experiencing. One approach to meet these challenges is to promote innovation by joining forces with partners such as biotech companies, other pharmaceutical companies, and academia. Such open innovation concepts are now gaining increasing importance. Whereas classical in-licensing or mergers and acquisitions (M&As) have been traditionally pursued, early research collaborations aiming to enrich the idea pool and de-risk early research projects are gaining interest. Novel models are arising, such as crowdsourcing initiatives or concepts based on the sharing of tools and assets. These endeavors are matched with a rise in interest in academia to contribute to drug discovery, resulting in the establishment of academic screening centers or open access initiatives. This is strengthened by the recent announcement of the NIH to increase the engagement of the NIH in drug discovery. This development is on the one hand driven by governments to get a return of their investment in research and on the other hand by the movement of scientists to more clinically focused research and an interest in bringing their findings to the clinic. We discuss novel open innovation models to foster early drug discovery such as Grants4targets, Call for targets or Pharma in-partnering. Furthermore, novel approaches to share tools and assets will be described such as the probe program of the Structural Genomics Consortium. Besides innovative models, the chapter will highlight requirements within the industry to ensure the uptake and further development of innovative ideas.

Cite this work

No public copy is stored for this record, so only the metadata is cited.

Stored only when both papers are in the corpus — 5 citations exist upstream.

Papers that cite the same references — the relational fallback while embeddings are still backfilling.